KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Income towards Parent Company: 2010-2025

Historic Income towards Parent Company for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Income towards Parent Company rose 5.58% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.90% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Income towards Parent Company of -$35.0 million as of Q3 2025, which was up 10.76% from -$39.2 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Income towards Parent Company high stood at $7.2 million for Q4 2024, and its period low was -$159.1 million during Q2 2022.
  • For the 3-year period, Nektar Therapeutics' Income towards Parent Company averaged around -$46.9 million, with its median value being -$42.1 million (2023).
  • Per our database at Business Quant, Nektar Therapeutics' Income towards Parent Company plummeted by 56.90% in 2021 and then spiked by 117.19% in 2024.
  • Nektar Therapeutics' Income towards Parent Company (Quarterly) stood at -$146.9 million in 2021, then spiked by 54.66% to -$66.6 million in 2022, then skyrocketed by 36.82% to -$42.1 million in 2023, then surged by 117.19% to $7.2 million in 2024, then climbed by 5.58% to -$35.0 million in 2025.
  • Its last three reported values are -$35.0 million in Q3 2025, -$39.2 million for Q2 2025, and -$46.4 million during Q1 2025.